Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 edition),Liver Cancer

当前位置： X-MOL 学术 › Liver Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 edition)
Liver Cancer ( IF 13.8 ) Pub Date : 2022-07-20 , DOI: 10.1159/000526038
Yu Yang ₁ , Juxian Sun ₂ , Mengchao Wu ₂ , Wan Yee Lau _{2,

3} , Shusen Zheng ₄ , Xue-Hao Wang ₅ , Xiaoping Chen ₆ , Jia Fan ₇ , Jiahong Dong ₈ , Jianqiang Cai ₉ , Minshan Chen ₁₀ , Yongjun Chen ₁₁ , Zhangjun Cheng ₁₂ , Chaoliu Dai ₁₃ , Jianzhen Shan ₁₄ , Cheng-You Du ₁₅ , Chihua Fang ₁₆ , Heping Hu ₁₇ , Zhili Ji ₁₈ , Weidong Jia ₁₉ , Gong Li ₂₀ , Jing Li ₂₁ , Jiangtao Li ₂₂ , Chang Liu ₂₃ , Fubao Liu ₂₄ , Yong Ma ₂₅ , Yilei Mao ₂₆ , Zuoxing Niu ₂₇ , Jie Shen ₂₈ , Jie Shi ₂ , Xuetao Shi ₂₉ , Wenjie Song ₃₀ , Hui-Chuan Sun ₇ , Guang Tan ₃₁ , Ran Tao ₃₂ , Xiaohu Wang ₃₃ , Tianfu Wen ₃₄ , Liqun Wu ₃₅ , Jinglin Xia ₃₆ , Bang-De Xiang ₃₇ , Maolin Yan ₃₈ , Mingang Ying ₃₉ , Ling Zhang ₄₀ , Xuewen Zhang ₄₁ , Zhao Chong Zeng ₄₂ , Yubao Zhang ₄₃ , Zhiwei Zhang ₄₄ , Jie Zhou ₄₅ , Cuncai Zhou ₄₆ , Jun Zhou ₄₇ , Ledu Zhou ₄₈ , Xinmin Zhou ₄₉ , Ji Zhu ₅₀ , Zhenyu Zhu ₅₁ , Qi Zhang ₅₂ , Qiu Li ₁ , Shuqun Cheng ₂

Affiliation

Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Hangzhou, China.
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Hepatic Surgery Center, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai, China.
Department of Hepatobiliary and Pancreas Surgery, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China.
Department of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Department of Hepatobiliary Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Hepatobiliary Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Department of Hepatobiliary and Spleenary Surgery, The Affiliated Shengjing Hospital, China Medical University, Shenyang, China.
Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Hepatobiliary Surgery, Zhujiang Hospital, First Military Medical University, Guangzhou, China.
Department of Gastroenterology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Department of General Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Department of General Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Department of Radiation Oncology, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China.
Department of Hepatobiliary Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC and Chinese Academy of Medical Sciences, Beijing, China.
Department of Gastroenterology, Shandong Cancer Hospital, Jinan, China.
Department of Medical Oncology, Cancer Center, Nanjing Drum Tower Hospital, Medical College of Nanjing University, Nanjing, China.
Department of Hepatobiliary Surgery, Shandong Cancer Hospital, Jinan, China.
Department of Hepatobiliary Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Department of Hepatobiliary Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China.
Department of Radiation Oncology, Gansu Cancer Hospital, Lanzhou, China.
Department of Liver Surgery, Center of Liver Transplantation, West China Hospital, Sichuan University, Chengdu, China.
Division of Hepatobiliary Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Hepatobiliary Surgery, Cancer Hospital Affiliated to Guangxi Medical University, Nanning, China.
Department of Hepatobiliary and Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, China.
Department of Abdominal Surgery, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital, Fuzhou, China.
Department of Hepatobiliary Surgery, Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Department of Hepatobiliary and Pancreas Surgery, The Second Hospital of Jilin University, Changchun, China.
Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Hepatobiliary Surgery, Cancer Hospital Affiliated to Harbin Medical University, Harbin, China.
Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Department of Hepatobiliary Surgery, Jiangxi Provincial Cancer Hospital, Jiangxi, China.
Department of Medical Oncology, Beijing Cancer Hospital, Beijing, China.
Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China.
Department of Gastroenterology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Department of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China.
Department of Hepatobiliary Surgery, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are firstly diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment. Summary: In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular targeted agents. To better guide the clinical treatment for effective and safe use of immunotherapeutic drugs, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the “Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021)” based on current clinical studies and clinical medication experience for reference in China. Key messages: The consensus contained 17 recommendations, including the preferred regimen for first- and second-line immunotherapy, evaluation and monitoring before/during/after treatment, management of complications, precautions for special patients and potential population for immunotherapy.

更新日期：2022-07-20

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>